GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Ajanta Pharma Ltd

Ajanta Pharma Q2 FY27 Consolidated Net Profit Rises 49% to Rs. 388 cr.

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 30 Oct 2026, 12:55 PM IST  ·  BSE ID: c5e4030f-ec7e-49bc-88cb-d6db676ebb6d
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's quarterly revenue increased by 33% and profits by 49%, with strong half-year performance.
🤖 AI Summary
  • Ajanta Pharma's Q2 FY2027 consolidated revenue from operations increased 33% year-on-year to Rs. 1,794 cr.
  • Consolidated Profit after tax (PAT) for Q2 FY2027 grew 49% year-on-year to Rs. 388 cr.
  • Half-year FY2027 consolidated revenue was Rs. 3,420 cr., marking a 29% increase over H1 FY2026.
  • Half-year FY2027 consolidated PAT reached Rs. 722 cr., a 40% growth compared to H1 FY2026.
  • The Board of Directors approved the unaudited financial results for the quarter and half year ended 30th September 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Q2 FY2027 Revenue from operations
Rs. 1,794 cr.
33%
Q2 FY2027 Profit after tax
Rs. 388 cr.
49%
H1 FY2027 Revenue from operations
Rs. 3,420 cr.
29%
H1 FY2027 Profit after tax
Rs. 722 cr.
40%
H1 FY2027 ROCE
41%
H1 FY2027 RONW
31%
Q2 FY2027 R&D expense
₹ 72 cr.
🏢 How This Affects the Company
📈
Business Impact
The company's revenue growth of 33% in Q2 FY2027 and 29% in H1 FY2027 suggests expansion across its branded generics and US generic segments. India branded generic performance exceeded IPM growth by 27%, driven by new launches.
💰
Financial Impact
Profit after tax increased significantly by 49% in Q2 FY2027 and 40% in H1 FY2027, indicating improved profitability. ROCE stood at 41% and RONW at 31% for H1 FY2027.
⚙️
Operational Impact
Growth in segments like Africa branded generics (41% Q2, 35% H1) and US generics (41% Q2, 49% H1) indicates successful market penetration and operational execution in these regions. The company commercialized 52 ANDAs by H1 FY2027.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, reflecting increased revenue and profit generation, which impacts the company's intrinsic value.
🔍
Management Signal
The decision to approve and release the unaudited financial results and conduct an earnings call indicates transparency and adherence to regulatory reporting requirements.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY2027 results — monitor revenue and profit growth trends across segments.
ANDA approvals — track US FDA approvals for new generic product launches.
Investor presentation and conference call transcript — review detailed management commentary.
LOW RISK The filing indicates strong financial performance and positive growth across most segments.
💡 Investor Takeaway
Ajanta Pharma reported Q2 FY2027 consolidated revenue from operations at Rs. 1,794 cr., up 33% YoY. Profit after tax increased 49% to Rs. 388 cr. for the quarter. H1 FY2027 revenue reached Rs. 3,420 cr., growing 29%, with PAT at Rs. 722 cr., up 40%.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY2027 consolidated revenue from operations grew 33% to Rs. 1,794 cr., and Profit after tax (PAT) increased 49% to Rs. 388 cr.
  • Africa branded generics revenue rose 41% to ₹ 312 cr. in Q2 FY2027 and US Generic revenue increased 41% to ₹ 484 cr.

⚠️ Concerns

  • Growth in the Asia branded generics segment for H1 FY2027 was 1%, a decrease from 18% in Q2 FY2027, indicating slower expansion in that region.
  • Cardiology segment growth of 13% in India was lower than the overall IPM growth of 17% for the period ending September 2026.
📅 Company Track Record
Ajanta Pharma has reported healthy Revenue and PAT CAGR of 14% over the last three financial years. The company's board had previously scheduled the Q4 FY26 results approval for May 5, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Ajanta Pharma's consolidated revenue from operations in Q2 FY2027?
Ajanta Pharma's consolidated revenue from operations for Q2 FY2027 was Rs. 1,794 cr., representing a 33% increase compared to Q2 FY2026.
What was Ajanta Pharma's Profit After Tax (PAT) for the half-year ended September 30, 2026?
The consolidated Profit after tax for Ajanta Pharma for H1 FY2027 was Rs. 722 cr., showing a 40% growth compared to H1 FY2026.
How did Ajanta Pharma's US Generic business perform in Q2 FY2027?
The US Generic business revenue for Ajanta Pharma increased by 41% to Rs. 484 cr. in Q2 FY2027 compared to Q2 FY2026.
What were Ajanta Pharma's ROCE and RONW for H1 FY2027?
Ajanta Pharma's Return on Capital Employed (ROCE) stood at 41% and Return on Net Worth (RONW) at 31% for H1 FY2027.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.